10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2013 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2013 10-K (Filed: Feb 14, 2014) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2013 | Dec 31, 2012 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 3,586 | 1,656 |
| Marketable securities, current | 939 | 1,173 |
| Receivables | 3,360 | 3,083 |
| Inventories | 1,498 | 1,657 |
| Deferred income taxes, current | 1,701 | 1,597 |
| Prepaid expenses and other | 412 | 355 |
| Assets held-for-sale | 7,420 | |
| Total Current Assets | 18,916 | 9,521 |
| Property, plant and equipment | 4,579 | 5,333 |
| Goodwill | 7,096 | 7,635 |
| Other intangible assets | 2,318 | 8,778 |
| Deferred income taxes | 508 | 203 |
| Marketable securities, noncurrent | 3,747 | 3,523 |
| Other assets | 1,428 | 904 |
| Total Assets | 38,592 | 35,897 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term borrowings and current portion of long-term debt | 359 | 826 |
| Accounts payable | 2,559 | 2,202 |
| Accrued expenses | 2,152 | 2,573 |
| Deferred income, current | 756 | 825 |
| Accrued rebates and returns | 889 | 1,054 |
| Income taxes payable, current | 160 | 193 |
| Dividends payable | 634 | 606 |
| Liabilities related to assets held-for-sale | 4,931 | |
| Total Current Liabilities | 12,440 | 8,279 |
| Pension, postretirement, and postemployment liabilities | 718 | 1,882 |
| Deferred income, noncurrent | 769 | 4,024 |
| Income taxes payable, noncurrent | 750 | 648 |
| Deferred income taxes | 73 | 383 |
| Other liabilities | 625 | 475 |
| Long-term debt | 7,981 | 6,568 |
| Total Liabilities | 23,356 | 22,259 |
| Commitments and contingencies (Note 22) | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,369 in 2013 and 5,117 in 2012, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2013 and 2012 | 221 | 221 |
| Capital in excess of par value of stock | 1,922 | 2,694 |
| Accumulated other comprehensive loss | (2,141) | (3,202) |
| Retained earnings | 32,952 | 32,733 |
| Less cost of treasury stock - 559 million common shares in 2013 and 570 million in 2012 | (17,800) | (18,823) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 15,154 | 13,623 |
| Noncontrolling interest | 82 | 15 |
| Total Equity | 15,236 | 13,638 |
| Total Liabilities and Equity | 38,592 | 35,897 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |